poisar

Stocks · News reference

Immunovant’s IMVT-1402 600mg Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Trial; 300mg Dose Shows No Difference From Placebo

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading